Upcoming Events
DISCLAIMER: THIS SITE DOES NOT PROVIDE MEDICAL ADVICE
The information on this webpage and these webinars is intended for educational and informative purposes only and is not intended as a substitute for medical or professional advice, diagnosis or treatment. Always seek the advice of your doctor or other qualified health care provider with regards to any questions you may have regarding a medical condition or treatment before undertaking a health care regimen. Never disregard or delay seeking professional medical advice because of information you have read or seen on this website. The opinions stated in these webinars are those of the people speaking and not necessarily of AONM.
SPEAKER: Professor Dr. med. Katharina Pachmann
TITLE: Evaluation of The Clinical Potential in Prostate Cancer Using Maintrac®
Exploring the use of circulating epithelial tumour cell tracking (CETCs) to inform personalised and integrative approaches in cancer support
DATE: Tuesday 2nd December 2025
TIME: 7:00PM GMT | 8:00PM CET | 2:00PM EST
DESCRIPTION:
Prostate cancer remains the most common cancer among men, with risk increasing significantly with age. Many cases involve slow-growing, less aggressive tumours that can develop slowly over a period of many years. To help avoid overtreatment in these low-risk patients, “active monitoring” and “watch-and-wait” approaches are often adopted, allowing for careful observation over time.
For practitioners supporting clients with a diagnosis of prostate cancer, gaining reliable insights into tumour behaviour without invasive procedures can be invaluable. Maintrac®, a liquid biopsy method, offers a new dimension of understanding, enabling tumour activity to be assessed directly without the need for invasive interventions or imaging. In more advanced cases, Stemtrac® can also be used to track circulating stem cells, offering additional information on tumour cell behaviour.
In this upcoming webinar, Professor Katharina Pachmann, a pioneer in the field of liquid biopsy and circulating tumour cell (CTC) analysis, will present how Maintrac® and Stemtrac® technologies are transforming the monitoring and management of prostate cancer, including how effective therapeutic approaches are likely to be. She will also present their latest scientific study exploring the role of Maintrac® during radiotherapy, and how these innovative methods can contribute to optimising therapy decisions.
Professor Katharina Pachmann will also discuss the analysis of key therapy-relevant biomarkers on circulating tumour cells, including Prostate-Specific Antigen (PSA), Prostate-Specific Membrane Antigen (PSMA), the Androgen Receptor (AR), and B7-H3.
—————————————————
ABOUT THE SPEAKER
Professor Dr. med. Katharina Pachmann runs the Maintrac laboratory in Bayreuth, Germany, together with Dr. Ulrich Pachmann and a team of 45. As both a medical doctor and research scientist, she has been conducting studies in this field and refining related techniques for over two decades, and has authored over a hundred peer-reviewed scientific publications on the technique.
—————————————————
Register here: www.aonm.org/prostatecancerpachmann
IMPORTANT NOTE: Maintrac is not intended to be used as a diagnostic or screening approach. It may be used for tracking the progression or remission of tumours of epithelial origin through its detection of circulating epithelial tumour cells (CETCs) in the blood. The approach has multiple applications, including helping to inform clinical judgment in the provision of functional or integrative support for patients or clients. The tests need to be overseen by a registered medical practitioner if Maintrac is to be used to inform cancer treatment directly, or to monitor the interaction of chemotherapeutic agents with the cells being tested.